{"nctId":"NCT03276936","briefTitle":"A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea","startDateStruct":{"date":"2017-09-05","type":"ACTUAL"},"conditions":["Papulopustular Rosacea"],"count":504,"armGroups":[{"label":"Minocycline Foam 1.5%","type":"EXPERIMENTAL","interventionNames":["Drug: FMX103 1.5%"]}],"interventions":[{"name":"FMX103 1.5%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Have completed 12 weeks of treatment in either Study FX2016-11 or Study FX2016-12.\n2. Have not had a worsening of disease, determined by the Investigator's Global Assessment (IGA), at Visit 5/Week 12 (Final Visit) relative to the Day 0/Baseline assessment in Study FX2016-11 or Study FX2016-12.\n\nExclusion Criteria:\n\n1. Have a new systemic disease or condition, including an ongoing AE that might interfere with the conduct of the study or the interpretation of results.\n2. Have developed a condition that would have been exclusionary for Study FX2016-11 or Study FX2016-12, including pseudomembranous colitis, antibiotic associated colitis, hepatitis, liver damage, renal impairment, drug addiction, or alcohol abuse.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change From Baseline in Inflammatory Lesion Count at Week 40","description":"Change from Baseline (Baseline visit in the initial DB study \\[FX2016-11 or FX2016-12\\] and Baseline visit of the open-label extension study \\[Week 12\\]) in inflammatory lesion count at Week 40 is reported. The lesion counts performed at Week 12 \\[Final Visit\\] in Study FX2016-11 or Study FX2016-12 constituted as the Baseline value for this study. Changes from Baseline were calculated as the Baseline \\[pre-dose\\] value minus the post-Baseline value, so that decreases reflected a reduction in lesion count. The number of papules, pustules, and nodules were counted, and the numbers recorded.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":"10.96"},{"groupId":"OG001","value":"22.5","spread":"10.83"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Investigator's Global Assessments (IGA) Treatment Success at Week 40","description":"The IGA scale for Rosacea, was used by the Investigators to assess the severity of a participant's Rosacea. The scale ranges from 0 (Clear): No inflammatory papules or pustules to 4 (Severe): Many inflammatory papules or pustules, and up to 2 nodules. Higher scores indicated severe outcome. Treatment success was defined as an IGA score of 0 (score of clear) or 1 (almost clear), and at least a 2-grade improvement (decrease) from Baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null},{"groupId":"OG001","value":"76.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Inflammatory Lesion Count at Weeks 4, 10, 16, 22, 28, and 34","description":"Change from Baseline (Baseline visit in the initial DB study \\[FX2016-11 or FX2016-12\\] and Baseline visit of the open-label extension study \\[Week 12\\]) in inflammatory lesion count at Week 40 is reported. The lesion counts performed at Week 12 \\[Final Visit\\] in Study FX2016-11 or Study FX2016-12 constituted as the Baseline value for this study. Changes from Baseline were calculated as the Baseline \\[pre-dose\\] value minus the post-Baseline value, so that decreases reflected a reduction in lesion count. The number of papules, pustules, and nodules were counted, and the numbers recorded.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":"11.57"},{"groupId":"OG001","value":"17.4","spread":"12.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":"11.62"},{"groupId":"OG001","value":"19.8","spread":"12.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":"11.38"},{"groupId":"OG001","value":"20.0","spread":"13.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":"12.35"},{"groupId":"OG001","value":"20.7","spread":"11.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":"11.89"},{"groupId":"OG001","value":"21.7","spread":"10.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":"11.75"},{"groupId":"OG001","value":"22.5","spread":"10.71"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving IGA Treatment Success at Weeks 4, 10, 16, 22, 28 and 34","description":"The IGA scale for Rosacea, was used by the Investigators to assess the severity of a participant's Rosacea. The scale ranges from 0 (Clear): No inflammatory papules or pustules to 4 (Severe): Many inflammatory papules or pustules, and up to 2 nodules. Higher scores indicated severe outcome. Treatment success was defined as an IGA score of 0 (score of clear) or 1 (almost clear), and at least a 2-grade improvement (decrease) from Baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6","spread":null},{"groupId":"OG001","value":"48.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.1","spread":null},{"groupId":"OG001","value":"54.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","spread":null},{"groupId":"OG001","value":"64.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.1","spread":null},{"groupId":"OG001","value":"64.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"65.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","spread":null},{"groupId":"OG001","value":"72.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Inflammatory Lesion Count at Weeks 4, 10, 16, 22, 28, and 34","description":"Change from Baseline (Baseline visit in the initial DB study \\[FX2016-11 or FX2016-12\\] and Baseline visit of the open-label extension study \\[Week 12\\]) in inflammatory lesion count at Week 40 is reported. The lesion counts performed at Week 12 \\[Final Visit\\] in Study FX2016-11 or Study FX2016-12 constituted as the Baseline value for this study. Changes from Baseline were calculated as the Baseline \\[pre-dose\\] value minus the post-Baseline value, so that decreases reflected a reduction in lesion count. The number of papules, pustules, and nodules were counted, and the numbers recorded.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.91","spread":"27.569"},{"groupId":"OG001","value":"61.25","spread":"32.306"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.43","spread":"27.937"},{"groupId":"OG001","value":"69.02","spread":"32.966"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.36","spread":"22.739"},{"groupId":"OG001","value":"71.46","spread":"33.230"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.51","spread":"25.101"},{"groupId":"OG001","value":"73.63","spread":"27.515"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.82","spread":"23.439"},{"groupId":"OG001","value":"77.06","spread":"25.863"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.91","spread":"20.549"},{"groupId":"OG001","value":"80.38","spread":"22.873"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Satisfaction and Dissatisfaction With the Study Drug Based on Subject Satisfaction Questionnaire (SSQ) at Week 40","description":"The questionnaire consisted of questions with responses on scale with scores: as 1 (Very satisfied or Very likely ) to 5 (Very dissatisfied or Very unlikely) for each variable as for example, Easy to use, 1 is very satisfied and 5 is very dissatisfied. The minimum score represented best outcome and higher score represented worst outcome.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"183","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","description":"Evaluation of the long-term safety of topical FMX103 1.5% minocycline foam in the treatment of moderate to severe facial papulopustular rosacea for 40 weeks. A Treatment-emergent Adverse Events (TEAEs) was defined as any AE with an onset date after the first dose date of the open-label extension study and before the last application of study drug plus 3 days having been absent pre-treatment or worsened relative to the pre-treatment state.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":332},"commonTop":["Sinusitis"]}}}